文献速递胸部肿瘤

最大径小于30 mm的非小细胞肺癌脏层胸膜侵犯与肺实质侵犯的生存分析

Survival with Parenchymal and Pleural Invasion of Non-Small Cell Lung Cancers Less than 30 mm.
PubMed 文献 · J Thorac Oncol · 2019-01-24

研究基于前瞻性筛查队列,按病理肿瘤大小(≤10 mm、11–20 mm、21–30 mm)和结节实性成分分层,分析脏层胸膜侵犯(VPI)和肺实质侵犯(PAI)对最大径小于30 mm的非小细胞肺癌(NSCLC)长期生存的影响。结果显示,亚实性结节的PAI发生率显著低于实性结节(4.9% vs 27.7%,p<0.0001),肺癌生存率显著更高(99.1% vs 91.3%,p=0.0009)。多因素Cox回归中仅肿瘤直径(校正HR=1.07,95%CI:1.01–1.14,p=0.02)和PAI(校正HR=3.15,95%CI:1.25–7.90,p=0.01)为独立预后因素,VPI无统计学意义(p=0.15)。

要点

  • 亚实性结节PAI发生率显著低于实性结节(4.9% vs 27.7%,p<0.0001),肺癌生存率显著更高(99.1% vs 91.3%,p=0.0009)。
  • 多因素Cox回归中,肿瘤直径(校正HR=1.07,95%CI:1.01–1.14,p=0.02)和PAI(校正HR=3.15,95%CI:1.25–7.90,p=0.01)为独立预后因素,VPI无统计学意义(p=0.15)。
  • 纳入临床和CT特征后,实性结节肺癌死亡风险增加10倍(HR=10.06,95%CI:1.35–75.30),中重度肺气肿风险增加2.27倍(HR=2.27,95%CI:1.01–5.11),PAI不再显著(p=0.19)。

核心结论

  • CT上的结节实性成分是比PAI或VPI更显著的预后指标。
  • 作者提出,对于最大径不超过30 mm且伴VPI的NSCLC患者,在没有进一步大型多中心研究按新T分期分层的前提下,不应将其上调为T2。
  • 作者提出,应考虑将亚实性结节与实性结节患者分别进行分类。

研究设计与样本

  • 研究为前瞻性筛查队列,按病理肿瘤大小(≤10 mm、11–20 mm、21–30 mm)和结节实性成分分层,纳入最大径小于30 mm的NSCLC患者。

主要发现

  • 亚实性结节患者PAI发生率显著低于实性结节患者(4.9% vs 27.7%,p<0.0001)。
  • 亚实性结节患者肺癌Kaplan-Meier生存率显著高于实性结节患者(99.1% vs 91.3%,p=0.0009)。
  • 多因素Cox回归中,肿瘤直径(校正HR=1.07,95%CI:1.01–1.14,p=0.02)和PAI(校正HR=3.15,95%CI:1.25–7.90,p=0.01)与肺癌死亡风险显著相关,VPI无统计学意义(p=0.15)。
  • 纳入临床和CT特征后,实性结节患者肺癌死亡风险增加10倍(HR=10.06,95%CI:1.35–75.30),中重度肺气肿患者风险增加2.27倍(HR=2.27,95%CI:1.01–5.11),肿瘤直径增加与风险升高相关(HR=1.06,95%CI:1.01–1.13),PAI不再显著(p=0.19)。

关键数值与推荐

  • PAI与VPI的发生率在亚实性结节中为4.9%,在实性结节中为27.7%(p<0.0001)。
  • 肺癌生存率在亚实性结节中为99.1%,在实性结节中为91.3%(p=0.0009)。
  • 多因素Cox回归中,肿瘤直径校正HR=1.07(95%CI:1.01–1.14,p=0.02),PAI校正HR=3.15(95%CI:1.25–7.90,p=0.01),VPI p=0.15。
  • 纳入临床和CT特征后,实性结节HR=10.06(95%CI:1.35–75.30),中重度肺气肿HR=2.27(95%CI:1.01–5.11),肿瘤直径HR=1.06(95%CI:1.01–1.13),PAI p=0.19。

临床怎么用

  • 作者提出,对于最大径不超过30 mm且伴VPI的NSCLC患者,在没有进一步大型多中心研究按新T分期分层的前提下,不应将其上调为T2。
  • 作者提出,应考虑将亚实性结节与实性结节患者分别进行分类。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine long-term survival of visceral pleural invasion (VPI) and parenchymal invasion (PAI) (angiolymphatic and/or vascular) on survival of NSCLCs less than 30 mm in maximum diameter. METHODS: Kaplan-Meier survivals for NSCLCs, with and without VPI and/or PAI, were determined for a prospective cohort of screening participants stratified by pathologic tumor size (≤10 mm, 11-20 mm, and 21-30 mm) and nodule consistency. Log-rank test statistics were calculated. RESULTS: The frequency of PAI versus VPI was significantly lower in patients with subsolid nodules than in those with solid nodules (4.9% versus 27.7% [p < 0.0001]), and correspondingly, Kaplan-Meier lung cancer survival was significantly higher among patients with subsolid nodules (99.1% versus 91.3% [p = 0.0009]). Multivariable Cox regression found that only tumor diameter (adjusted hazard ratio [HR] =1.07, 95% confidence interval [CI]: 1.01-1.14, p = 0.02) and PAI (adjusted HR = 3.15, 95% CI: 1.25-7.90, p = 0.01) remained significant, whereas VPI was not significant (p = 0.15). When clinical and computed tomography findings were included with the pathologic findings, Cox regression showed that the risk of dying of lung cancer increased 10-fold (HR = 10.06, 95% CI: 1.35-75.30) for NSCLCs in patients with solid nodules and more than twofold (by a factor of 2.27) in patients with moderate to severe emphysema (HR = 2.27, 95% CI: 1.01-5.11), as well as with increasing tumor diameter (HR = 1.06, 95% CI: 1.01-1.13), whereas PAI was no longer significant (p = 0.19). CONCLUSIONS: Nodule consistency on computed tomography was a more significant prognostic indicator than either PAI or VPI. We propose that patients with NSCLC with VPI and a maximum tumor diameter of 30 mm or less not be upstaged to T2 without further large, multicenter studies of NSCLCs, stratified by the new T status and that classification be considered separately for patients with subsolid or solid nodules.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Yip R, Ma T, Flores RM, et al. Survival with Parenchymal and Pleural Invasion of Non-Small Cell Lung Cancers Less than 30 mm. J Thorac Oncol. 2019. PMID: 30685507. doi:10.1016/j.jtho.2019.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。